Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
P/S ratio for Theratechnologies Inc. (THTX)
P/S ratio as of 2023: 0.51
According to Theratechnologies Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.51. At the end of 2022 the company had a P/S ratio of 10.39.
P/S ratio history for Theratechnologies Inc. from 1996 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.51 |
| 2022 | 10.39 |
| 2021 | 17.42 |
| 2020 | 10.75 |
| 2019 | 14.88 |
| 2018 | 42.49 |
| 2017 | 47.54 |
| 2016 | 21.64 |
| 2015 | 13.56 |
| 2014 | 12.83 |
| 2013 | 8.40 |
| 2012 | 4.67 |
| 2011 | 37.97 |
| 2010 | 42.58 |
| 2009 | 45.50 |
| 2008 | 149.71 |
| 2007 | 681.11 |
| 2006 | 263.52 |
| 2005 | 8.81 |
| 2004 | 98.66 |
| 2003 | 149.42 |
| 2002 | 61.78 |
| 2001 | 259.88 |
| 2000 | 798.65 |
| 1999 | 250.22 |
| 1998 | 178.96 |
| 1997 | 754.80 |
| 1996 | 685.51 |